Sistema de Salut de Catalunya
[Escolà-Vergé L, Pigrau C, Almirante B] Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. Spanish Network for Research in Infectious Diseases (REIPI), Madrid, Spain.
Vall d'Hebron Barcelona Hospital Campus
2020-01-22T11:28:13Z
2020-01-22T11:28:13Z
2019-07-01
Tractament amb ceftolozane-tazobactam; Infeccions intra-abdominals; Infeccions del tracte superior urinari; Pseudomonas aeruginosa resistentent a medicaments
Tratamiento con ceftolozane-tazobactam; Infecciones intraabdominales; Infecciones del tracto superior urinario; Pseudomonas aeruginosa resistentes a medicamentos
Ceftolozane-tazobactam; Complicated intra-abdominal infections; Complicated urinary tract infections; Multidrug-resistant pseudomonas aeruginosa
The current prevalence of infections caused by multidrug-resistant (MDR) organisms is a global threat, and thus, the development of new antimicrobial agents with activity against these pathogens is a healthcare priority. Ceftolozane–tazobactam (C/T) is a new combination of a cephalosporin with a β-lactamase inhibitor that shows excellent in vitro activity against a broad spectrum of Enterobacteriaceae and Pseudomonas aeruginosa, including extended spectrum β-lactamase-producing (ESBL) strains and MDR or extensively drug-resistant (XDR) P. aeruginosa. In phase III randomized clinical trials, C/T demonstrated similar efficacy to meropenem for the treatment of complicated intra-abdominal infections (cIAIs) and superior efficacy to levofloxacin for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. The drug is generally safe and well tolerated and its PK/PD profile is very favorable. Observational studies with C/T have revealed good efficacy for the treatment of different types of infection caused by MDR or XDR P. aeruginosa, including some that originated from the digestive or urinary tracts. The place of C/T in therapy is not well defined, but its use could be recommended in a carbapenem-sparing approach for the treatment of infections caused by ESBL-producing strains or for the treatment of infections caused by P. aeruginosa if there are no other more favorable therapeutic options. Further clinical experience is needed to position this new antimicrobial drug for the empirical treatment of cIAIs or cUTIs.
The authors are funded by the Plan Nacional de I+D+I 2013-2016 and the Instituto de Salud Carlos III, Spain [REIPI RD16/0016/0003]
Article
Published version
English
Resistència als medicaments; Aparell urinari - Infeccions; Intraabdominal - Infeccions; DISEASES::Bacterial Infections and Mycoses::Infection::Intraabdominal Infections; DISEASES::Bacterial Infections and Mycoses::Infection::Urinary Tract Infections; PHENOMENA AND PROCESSES::Microbiological Phenomena::Drug Resistance, Microbial; FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::resistencia a medicamentos; ENFERMEDADES::infecciones bacterianas y micosis::infección::infecciones urinarias; ENFERMEDADES::infecciones bacterianas y micosis::infección::infecciones intraabdominales
Dovepress
Infection and Drug Resistance;12
https://www.dovepress.com/infection-and-drug-resistance-journal
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - HVH [3440]
